At its launch, Woodford said the Income Focus Fund would not have any geographical limit and aim for a “high level of regular and sustainable income” with a target income of 5p per share per year.
Pharmaceutical giant Astrazeneca is the fund’s biggest holding, with a weighting of 7.39%.
Former long-term holding GlaxoSmithKline is notable in its absence from the new fund following Woodford’s claim his investment in the firm had been a “frustrating experience”.
Familiar names such as Imperial Brands and British American Tobacco make up 4.93% and 2.45% of the portfolio respectively while new names Card Factory and Topps Tiles also appear in the portfolio’s holdings.
